Genprex Inc (NASDAQ:GNPX) has moved one step closer to commercializing its flagship drug candidate Oncoprex by retaining pharmaceutical branding agency Addison Whitney.
The clinical-stage gene therapy company has developed the drug to treat non-small cell lung cancer treatment.
Addison Whitney will oversee the official naming process, which requires regulatory approval.
"Retaining Addison Whitney is an important step in bringing our drug candidate to market,” Chairman and CEO Rodney Varner said. "Obtaining regulatory approval of proprietary and non-proprietary drug names is a necessary step in securing marketing approval, and Addison Whitney has an impressive track record in obtaining such name approvals.”
The Austin-based company’s drug fights non-small cell lung cancer by transporting cancer-fighting genes to cancerous cells.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel